SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?


To: thebeach who wrote (241)2/11/1998 1:36:00 AM
From: Todd D. Wiener  Respond to of 783
 
Actually, BCHE is entering a stiff resistance area, defined by its recent downtrend from $32. The trendline runs right thru the current price, indicating that BCHE is either at a trading peak, or it is going to break through to challenge its old highs. I suspect the former may be true, because the stock has overextended itself. The market might need to see positive news, either from 3TC/quarterly results or from lamivudine approvals, before it nears $30 again.

Todd